AngioDynamics, Inc. (ANGO) Cash Flow Statement

The persistent negative gap between net income and operating cash flow is not a sign of high-quality earnings but rather a reflection of the company's cash management cycle. The large positive working capital swings, such as the $16.5M release in 2026Q4, appear to be the primary driver of positive OCF, masking the underlying operational cash burn. This suggests the company is liquidating assets or stretching payables to fund operations, a pattern that may not be sustainable.

The FCF margin has been erratic, ranging from -28.7% to +22.5% over the past ten quarters, indicating a lack of predictable cash generation. This volatility is directly tied to the large, unpredictable swings in working capital, which have overwhelmed the modest positive impact of depreciation and amortization. The company's ability to generate sustainable free cash flow remains unproven, as the positive quarters are not supported by net income.

The pattern of large, alternating positive and negative working capital adjustments suggests potential instability in inventory management, receivables collection, or payables timing. The company appears to be using its balance sheet as a cash buffer, with releases in one quarter often following builds in the next. This volatility makes cash flow forecasting difficult and raises questions about the underlying efficiency of the business operations.

The minimal capital intensity, with CapEx consistently below 3% of revenue, is unusual for a manufacturing-focused medical device company and may indicate a strategy of prioritizing cash preservation over long-term capacity expansion. This low reinvestment rate, combined with persistent operating losses, raises concerns about the company's ability to maintain its competitive position and fund future growth without external financing.